Owkin

Owkin

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.owkin.com

Last Round

Series B

Extension

Jun 8, 2022

Est. Valuation

$1B

Total Funding Raised

$124M

Company Overview

Owkin is a healthcare technology company that develops machine learning tools to enhance medical and biological research by integrating biomedical images, genomics, and clinical data for improved understanding of disease mechanisms and treatment outcomes.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Clinical Trials, Medical AI, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Subscription SaaS, Freemium

AI Layer

Application

Keywords

AI drug discoveryfederated learningclinical trial optimizationAI diagnosticsdrug target discoverytechbiooncology AIprivacy-preserving AIagentic AIpredictive modelsmultimodal datareal-world datadigital pathologyAI co-pilotbiomedical research AISubstra

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Owkin Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Owkin Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionJun 8, 2022
Strategic Investment & Series B ExtensionNov 18, 2021
Series A ExtensionJul 1, 2020
Series A ExtensionMar 7, 2019
Series A ExtensionMay 23, 2018
Series A
Jan 16, 2018

Key People

Founding team and executive leadership

Brian undefined

Chief Executive Officer

Executive Team

Pandu Kurniawan

Chief Executive Officer

Executive Team

Stella h

Principal CEO

Executive Team

Thomas Clozel

Chief Executive Officer And Co-founder

Founding Team

Owkin Investors

Notable investors and investment history

InvestorRounds
GVSeries A Extension
NJF CapitalSeries A, Series A Extension, Seed
Otium CapitalSeries A
F-Prime CapitalSeries A Extension
Eight Roads VenturesSeries A Extension
BpifranceSeries A Extension
Plug & Play VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 2, 2026

    Introduced Owkin Zero, an LLM fine-tuned on biology.

  • Mar 3, 2026

    Partnered with Consensus to integrate scientific literature intelligence.

Owkin Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Owkin Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Owkin's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range462
Year Founded2016
Last FundingJun 8, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.